期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 50, 期 -, 页码 30-37出版社
ELSEVIER
DOI: 10.1016/j.intimp.2017.06.005
关键词
Neuroinflammation; beta-Amyloid; Aldose reductase inhibitor; Sorbinil; Zopolrestat
资金
- National Key Technology R&D Program New Drug Innovation of China [2012ZX09301002-002-002]
- Natural Science Foundation of China [81303253]
- Korea Institute of Science and Technology (KIST) [44321012010]
Microglia-mediated neuroinflammation is a key risk factor to the development of Alzheimer' disease (AD). Aldose reductase (AR) has been found to be widely involved in inflammation-related diseases; however, whether aldose reductase inhibitors (ARIs) could be used to treat neuroinflammation is rarely reported. This study aims to evaluate the anti-neuroinflammatory effects of two major ARIs of Sorbinil (Sor) and Zopolrestat (Zol) in beta-amyloid protein (A beta)-induced microglia (BV-2). We find that Sor and Zol significantly inhibit TNF-alpha, IL-1 beta, IL-6 production from microglia in response to All stimulation. Mechanism study showed that Sor and Zol decreased the production of intracellular ROS which resulted in an effective inhibition on the phosphorylation of several protein kinase C (PKC) isoforms including PKC alpha/beta, delta, zeta/lambda and mu. Moreover, Sor and Zol inactivated PCKassociated IKK beta-I kappa B-NF-kappa B and mitogen-activated protein kinase (JNK, p38, ERK) inflammation pathways. In summary, our findings suggest that Sor and Zol could inhibit A beta-induced neuroinflammation by regulating ROS/ PKC-dependent NF-kappa B and MAPK signaling pathways, indicating that ARIs could be promising agents for treating inflammation-related neurodegenerative diseases such as AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据